Immunology of progressive multifocal leukoencephalopathy

Journal of NeuroVirology

Volumn 21, Issue 6, 2015, Pages 614-622

  Jelcic, Ivan ^a   Jelcic, Ilijas ^a   Faigle, Wolfgang ^a   Sospedra, Mireia ^a   Martin, Roland ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Adaptive immunity; Antigen specificity; CNS infection; JCV; Natalizumab; Progressive multifocal leukoencephalopathy

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN;

ANTIGEN SPECIFICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGY; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; JC VIRUS; VIROLOGY;

HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL;

EID: 84946480102     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-014-0294-y     Document Type: Review

References (60)

1. Aly L, Yousef S, Schippling S, Jelcic I, Breiden P, Matschke J, Schulz R, Bofill-Mas S, Jones L, Demina V, Linnebank M, Ogg G, Girones R, Weber T, Sospedra M, Martin R (2011) Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. Brain 134:2687–2702
2. Beltrami S, Gordon J (2014) Immune surveillance and response to JC virus infection and PML. J Neurovirol 20:137–149
3. Brew BJ, Davies NW, Cinque P, Clifford DB, Nath A (2010) Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 6:667–679
4. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113:4834–4840
5. Chalkias S, Dang X, Bord E, Stein MC, Kinkel RP, Sloane JA, Donnelly M, Ionete C, Houtchens MK, Buckle GJ, Batson S, Koralnik IJ (2014) JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis. Ann Neurol 75:925–934
6. Chapagain ML, Nerurkar VR (2010) Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier. J Infect Dis 202:184–191
7. Cinque P, Bossolasco S, Brambilla AM, Boschini A, Mussini C, Pierotti C, Campi A, Casari S, Bertelli D, Mena M, Lazzarin A (2003) The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol 9(Suppl 1):73–80
8. Cooper N, Arnold DM (2010) The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol 149:3–13
9. Dahlhaus S, Hoepner R, Chan A, Kleiter I, Adams O, Lukas C, Hellwig K, Gold R (2013) Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 84:1068–1074
10. Dang X, Koralnik IJ (2013) Gone over to the dark side: natalizumab-associated JC virus infection of neurons in cerebellar gray matter. Ann Neurol 74:503–505
11. Dang X, Vidal JE, Oliveira AC, Simpson DM, Morgello S, Hecht JH, Ngo LH, Koralnik IJ (2012) JC virus granule cell neuronopathy is associated with VP1 C terminus mutants. J Gen Virol 93:175–183
12. Diotti RA, Mancini N, Clementi N, Sautto G, Moreno GJ, Criscuolo E, Cappelletti F, Man P, Forest E, Remy L, Giannecchini S, Clementi M, Burioni R (2014) Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy. Antiviral Res 108:94–103
13. Du Pasquier RA, Autissier P, Zheng Y, Jean-Jacques J, Koralnik IJ (2005) Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies. AIDS 19:2069–2076
14. Du Pasquier RA, Koralnik IJ (2003) Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 9(Suppl 1):25–31
15. Du Pasquier RA, Kuroda MJ, Schmitz JE, Zheng Y, Martin K, Peyerl FW, Lifton M, Gorgone D, Autissier P, Letvin NL, Koralnik IJ (2003) Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1 (p36) in patients with proven or possible progressive multifocal leukoencephalopathy. J Virol 77:11918–11926
16. Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, Koralnik IJ (2004) A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 127:1970–1978
17. Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C, Gosert R, Hirsch HH (2009) Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 199:837–846
18. Frohman EM, Monaco MC, Remington G, Ryschkewitsch C, Jensen PN, Johnson K, Perkins M, Liebner J, Greenberg B, Monson N, Frohman TC, Douek D, Major EO (2014) JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol 71:596–602
19. Gasnault J, Kahraman M, de Herve MG G, Durali D, Delfraissy JF, Taoufik Y (2003) Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. AIDS 17:1443–1449
20. Gheuens S, Bord E, Kesari S, Simpson DM, Gandhi RT, Clifford DB, Berger JR, Ngo L, Koralnik IJ (2011) Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol 85:7256–7263
21. Gheuens S, Wuthrich C, Koralnik IJ (2013) Progressive multifocal leukoencephalopathy: why gray and white matter. Annu Rev Pathol 8:189–215
22. Gillespie SM, Chang Y, Lemp G, Arthur R, Buchbinder S, Steimle A, Baumgartner J, Rando T, Neal D, Rutherford G et al (1991) Progressive multifocal leukoencephalopathy in persons infected with human immunodeficiency virus, San Francisco, 1981–1989. Ann Neurol 30:597–604
23. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, Pace A, Cheung A, Chen LL, Berman M, Zein F, Wilson E, Yednock T, Sandrock A, Goelz SE, Subramanyam M (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68:295–303
24. Gorelik L, Reid C, Testa M, Brickelmaier M, Bossolasco S, Pazzi A, Bestetti A, Carmillo P, Wilson E, McAuliffe M, Tonkin C, Carulli JP, Lugovskoy A, Lazzarin A, Sunyaev S, Simon K, Cinque P (2011) Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J Infect Dis 204:103–114
25. Houff SA, Major EO, Katz DA, Kufta CV, Sever JL, Pittaluga S, Roberts JR, Gitt J, Saini N, Lux W (1988) Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 318:301–305
26. Jelcic I, Aly L, Binder TM, Jelcic I, Bofill-Mas S, Planas R, Demina V, Eiermann TH, Weber T, Girones R, Sospedra M, Martin R (2013) T cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donors. J Virol 87:3393–3408
27. Jilek S, Jaquiery E, Hirsch HH, Lysandropoulos A, Canales M, Guignard L, Schluep M, Pantaleo G, Du Pasquier RA (2010) Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol 9:264–272
28. Khanna N, Wolbers M, Mueller NJ, Garzoni C, Du Pasquier RA, Fux CA, Vernazza P, Bernasconi E, Viscidi R, Battegay M, Hirsch HH, Swiss HIVCS (2009) JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J Virol 83:4404–4411
29. Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353:369–374
30. Koralnik IJ, Du Pasquier RA, Kuroda MJ, Schmitz JE, Dang X, Zheng Y, Lifton M, Letvin NL (2002) Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol 168:499–504
31. Koralnik IJ, Du Pasquier RA, Letvin NL (2001) JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J Virol 75:3483–3487
32. Major EO (2010) Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 61:35–47
33. Major EO, Frohman E, Douek D (2013) JC viremia in natalizumab-treated patients with multiple sclerosis. N Engl J Med 368:2240–2241
34. Marshall LJ, Ferenczy MW, Daley EL, Jensen PN, Ryschkewitsch CF, Major EO (2014) Lymphocyte gene expression and JC virus noncoding control region sequences are linked with the risk of progressive multifocal leukoencephalopathy. J Virol 88:5177–5183
35. Martin-Blondel G, Bauer J, Cuvinciuc V, Uro-Coste E, Debard A, Massip P, Delisle MB, Lassmann H, Marchou B, Mars LT, Liblau RS (2013) In situ evidence of JC virus control by CD8+ T cells in PML-IRIS during HIV infection. Neurology 81:964–970
36. Metz I, Radue EW, Oterino A, Kumpfel T, Wiendl H, Schippling S, Kuhle J, Sahraian MA, Gray F, Jakl V, Hausler D, Bruck W (2012) Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol 123:235–245
37. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH (1971) Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1:1257–1260
38. Perkins MR, Ryschkewitsch C, Liebner JC, Monaco MC, Himelfarb D, Ireland S, Roque A, Edward HL, Jensen PN, Remington G, Abraham T, Abraham J, Greenberg B, Kaufman C, LaGanke C, Monson NL, Xu X, Frohman E, Major EO, Douek DC (2012) Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy. PLoS Pathog 8:e1003014
39. Planas R, Jelcic I, Schippling S, Martin R, Sospedra M (2012) Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol 42:790–798
40. Reid CE, Li H, Sur G, Carmillo P, Bushnell S, Tizard R, McAuliffe M, Tonkin C, Simon K, Goelz S, Cinque P, Gorelik L, Carulli JP (2011) Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. J Infect Dis 204:237–244
41. Ryschkewitsch CF, Jensen PN, Monaco MC, Major EO (2010) JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol 68:384–391
42. Schippling S, Kempf C, Buchele F, Jelcic I, Bozinov O, Bont A, Linnebank M, Sospedra M, Weller M, Budka H, Martin R (2013) JCV granule cell neuronopathy and GCN-IRIS under natalizumab treatment. Ann Neurol 74:622–626
43. Schneider-Hohendorf T, Philipp K, Husstedt IW, Wiendl H, Schwab N (2014) Specific loss of cellular L-selectin on CD4+ T cells is associated with PML development during HIV infection. AIDS 28:793–795
44. Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Gobel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfar A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kumpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H (2013) L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 81:865–871
45. Sindic CJ, Trebst C, Van Antwerpen MP, Frye S, Enzensberger W, Hunsmann G, Luke W, Weber T (1997) Detection of CSF-specific oligoclonal antibodies to recombinant JC virus VP1 in patients with progressive multifocal leukoencephalopathy. J Neuroimmunol 76:100–104
46. Stuve O (2008) The effects of natalizumab on the innate and adaptive immune system in the central nervous system. J Neurol Sci 274:39–41
47. Stuve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand'Maison F, Hemmer B, Monson NL, Racke MK (2006a) Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 63:1383–1387
48. Stuve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Hemmer B, Monson NL, Racke MK (2006b) Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59:743–747
49. Sundqvist E, Buck D, Warnke C, Albrecht E, Gieger C, Khademi M, Lima Bomfim I, Fogdell-Hahn A, Link J, Alfredsson L, Sondergaard HB, Hillert J, International Multiple Sclerosis Genetics C, Oturai AB, Hemme B, Kockum I, Olsson T (2014) JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants. PLoS Pathog 10:e1004084
50. Tan CS, Bord E, Broge TA Jr, Glotzbecker B, Mills H, Gheuens S, Rosenblatt J, Avigan D, Koralnik IJ (2012) Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy. J Acquir Immune Defic Syndr 60:244–248
51. Tan IL, McArthur JC, Clifford DB, Major EO, Nath A (2011) Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 77:1061–1067
52. Tan K, Roda R, Ostrow L, McArthur J, Nath A (2009) PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 72:1458–1464
53. Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A (2012) Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 78:1736–1742
54. Turner SJ, Doherty PC, McCluskey J, Rossjohn J (2006) Structural determinants of T-cell receptor bias in immunity. Nat Rev Immunol 6:883–894
55. Warnke C, Ramanujam R, Plavina T, Bergstrom T, Goelz S, Subramanyam M, Kockum I, Rahbar A, Kieseier BC, Holmen C, Olsson T, Hillert J, Fogdell-Hahn A (2013) Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry 84:1199–1205
56. Warnke C, von Geldern G, Markwerth P, Dehmel T, Hoepner R, Gold R, Pawlita M, Kumpfel T, Maurer M, Stangel M, Wegner F, Hohlfeld R, Straeten V, Limmroth V, Weber T, Hermsen D, Kleinschnitz C, Hartung HP, Wattjes MP, Svenningson A, Major E, Olsson T, Kieseier BC, Adams O (2014) Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. doi:10.1002/ana.24153
57. Weber T, Trebst C, Frye S, Cinque P, Vago L, Sindic CJ, Schulz-Schaeffer WJ, Kretzschmar HA, Enzensberger W, Hunsmann G, Luke W (1997) Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis 176:250–254
58. Wuthrich C, Kesari S, Kim WK, Williams K, Gelman R, Elmeric D, De Girolami U, Joseph JT, Hedley-Whyte T, Koralnik IJ (2006) Characterization of lymphocytic infiltrates in progressive multifocal leukoencephalopathy: co-localization of CD8 (+) T cells with JCV-infected glial cells. J Neurovirol 12:116–128
59. Yousef S, Planas R, Chakroun K, Hoffmeister-Ullerich S, Binder TM, Eiermann TH, Martin R, Sospedra M (2012) TCR bias and HLA cross-restriction are strategies of human brain-infiltrating JC virus-specific CD4+ T cells during viral infection. J Immunol 189:3618–3630
60. Zonios DI, Falloon J, Bennett JE, Shaw PA, Chaitt D, Baseler MW, Adelsberger JW, Metcalf JA, Polis MA, Kovacs SJ, Kovacs JA, Davey RT, Lane HC, Masur H, Sereti I (2008) Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors. Blood 112:287–294